ClinicalTrials.Veeva

Menu

Food Reward in Cachexia Induced by Acute or Chronic Disease

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status

Terminated

Conditions

Chronic Obstructive Pulmonary Disease
Non-small Cell Lung Cancer
Cachexia
Pancreatic Cancer

Treatments

Other: Functional magnetic resonance imaging (fMRI)

Study type

Observational

Funder types

Other

Identifiers

NCT02798003
NL54799.068.15

Details and patient eligibility

About

To study activity in the reward-circuitry of the brain in patients suffering from cachexia induced by cancer or chronic disease.

Full description

The activity in the food reward-circuitry of the brain in patients suffering from cachexia induced by cancer (lung cancer or pancreatic cancer) or chronic disease (chronic obstructive pulmonary disease) will be analysed by using functional magnetic resonance imaging. In addition, the role of the peripheral satiety hormones will be evaluated.

Enrollment

44 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • For cachectic patients: weight loss exceeds 5% of total body weight over the past 6 months, or >2% when body mass index is <20 kg/m2
  • For non-cachectic patients: no weight loss of ≥5% during the last 6 months
  • Non-small cell lung cancer or gastro-intestinal cancer, pathology proven or diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria

Exclusion criteria

  • Contra-indications for fMRI examination (operation to your head or brain in the past; implanted electronic devices, for instance a pacemaker, neurostimulator, cochlear or hearing implant; insulin pump under your skin; Pregnant subjects, claustrophobia; pregnancy; metal parts in your body (except from teeth filling and connectors): implants; brain vessel clamps, prostheses, intra-uterine device, metal splinter in the eye, metal braces or other metal objects, permanent eye make-up)
  • Psychiatric or other disorders likely to impact on informed consent
  • Presence of brain metastasis (screening is not mandatory)
  • Medical history of cerebrovascular accident, brain tumour, brain metastasis
  • Previous radiotherapy to brain, both stereotactic and whole brain radiotherapy
  • Memory problems
  • Current use of tube feeding or parental nutrition
  • Patients with an active second malignancy
  • Patients unable to lie still for 2 hours
  • Unable to complete the cognitive task
  • Pre-existing swallowing difficulties
  • Allergy to gluten-, milk- or wheat products
  • Self-reported hyperthyroidism
  • Self-reported diabetes mellitus
  • Current use of appetite stimulant medications

Trial design

44 participants in 4 patient groups

Cachectic cancer patients
Description:
Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
Treatment:
Other: Functional magnetic resonance imaging (fMRI)
Non-cachectic cancer patients
Description:
Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
Treatment:
Other: Functional magnetic resonance imaging (fMRI)
Cachectic COPD patients
Description:
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
Treatment:
Other: Functional magnetic resonance imaging (fMRI)
Non-cachectic COPD patients
Description:
Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
Treatment:
Other: Functional magnetic resonance imaging (fMRI)

Trial contacts and locations

1

Loading...

Central trial contact

Judith de Vos-Geelen, MD; Karin Sanders, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems